Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 4Endocrine 2CNS 1

Conditions

Neuroendocrine Tumors 148Carcinoma, Neuroendocrine 57Thyroid Cancer, Papillary 54Pheochromocytoma 52Thyroid Neoplasms 42Paraganglioma 42Pituitary Neoplasms 39Neoplasms 32Adrenocortical Carcinoma 31Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 24Lung Neoplasms 22Small Cell Lung Carcinoma 21Sarcoma 20Carcinoid Tumor 20Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Pancreatic Neoplasms 16Colorectal Neoplasms 16Adrenal Gland Neoplasms 16Prostatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Carcinoma, Renal Cell 15Adenocarcinoma, Follicular 15

Interventions

spartalizumab 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hereditary leiomyomatosis and renal cell cancer × Endocrine × 1 year × Clear all
NCT00001238 2026-05-22

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
5,000 enrolled
EndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms, Pheochromocytoma

NCT04895748 2026-03-03

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Novartis

Phase 1 Terminated
40 enrolled
CNSEndocrineGenitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡